Recombinant human interleukin-2(125Ser)(Shenzhen Neptunus Interlong Bio-Technique)

重组人白细胞介素-2（深圳市海王英特龙）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interleukin-2(125Ser)(Shenzhen Neptunus Interlong Bio-Technique)
Drug Alias Name英特康欣
ClassificationBiologics
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsUrinary Bladder NeoplasmsLung NeoplasmsLiver Neoplasms +[8] 
Global Approved IndicationsUrinary Bladder NeoplasmsLung NeoplasmsLiver Neoplasms +[8] 
Approved Indications in ChinaUrinary Bladder NeoplasmsLung NeoplasmsLiver Neoplasms +[8] 
Original Approved Country/TerritoryMainland China
Original Approved Date2005/01/24
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShenzhen Neptunus Interlong Bio-Technique Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Neptunus Interlong Bio-Technique Co Ltd
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsLung NeoplasmsLiver Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A